Guidance and expertise to accelerate market access and drive product adoption
We advise and guide pharma, device and biotechnology companies at every stage of development, from endpoint selection and PRO development, through clinical trials, to post-approval and scientific publication. Our commercial solutions include:
- Real world evidence - Our RWE strategy and analytics experts offer specialised consulting and technology solutions for the design and delivery of real world evidence studies. We help you optimise your evidence generation strategies to support a comprehensive asset value story.
- Health economics and outcomes - Using established methods and innovative tailored solutions to generate HEOR evidence, meet specific HTA challenges with early advice and submissions, support market access and bolster arguments for product reimbursement.
- Patient reported outcomes - Our patient outcomes experts consult at every stage of development, from endpoint selection and PRO development, to use in clinical trials, through post-approval and publication. We negotiate with international drug regulatory agencies and health care payers regarding the appropriate use of patient reported information in clinical trials, drug approval and drug reimbursement.
- Pricing, market accesss and reimbursement - ICON is an industry leader in strategic market access, with expertise in all major global markets, helping to define, capture and communicate the value of medical therapies for optimal commercial results and patient access.
Medical and value communications - Our experienced medical communications strategists and scientific experts develop and implement customised, strategically aligned communication plans to optimise the dissemination of your product's cllinical and outcomes data across your key audiences.
Insights and thought leadership
Pharma marketing in the digital age
Social media and digital technology are providing new opportunities for pharma marketers to make a fundamental difference.
ICER's impact on payer decision making
In the US, ICER has emerged as a leading voice in evaluating the clinical and economic value of healthcare technologies. Read our third annual payer survey.
COVID-19 impact on HTA and reimbursement requirements
We look at how the pandemic could impact existing product pipelines and existing HEOR evidence planning and timetables.
The value of PRO data to US payers
With the increase in patient centricity, we surveyed US payers from MCOs, IDNs and PBMs to get their take on the value and use of patient reported outcome data.